When digital rectal examinations (DREs) and particularly serum prostate-specific antigen (PSA) tests are used to screen for prostate cancer, more cancers are found in ear lier stages, This stage shift suggests that screening identifies more readily curable cancers and raises the possibility of reducing prostate specific cancer mortality rates. Alternatively. many early-stage cancers detected by screening may be less malignant than other cancers, which would limit their effect on mortality rates and thus our opportunity for reducing them. Which outcome will occur remains to be seen, 1,: Clinical trials are under way in the United States and Europe to answer this question, but they will require thousands of subjects and a decade or more of follow-up because of the long doubling times and favorable outcomes of most prostate cancers. Meanwhile, most U,S, physicians and their patients have embraced the goal of early detection of prostate cancer, pending the results of clinical studies, s An easier, faster way to deter mine whether screening does more good than harm would be most welcome, Case control studies may provide some answers. If these studies found that patients with advanced or fatal prostate cancer had been screened less frequently than control subjects, we might conclude that screening is pro tective, In the current practice of what some have called the "PSA era," however, nearly every patient with a new diagnosis of prostate cancer will have had a DRE and PSA test before the diagnosis, Therefore. a key methodologic issue in case-control studies is how to separate screening studies, which should be counted, from diagnostic stud ies, which should not be counted, In this issue Dr, Concato demonstrates why this task is not easy, 4
more of follow-up because of the long doubling times and favorable outcomes of most prostate cancers. Meanwhile, most U,S, physicians and their patients have embraced the goal of early detection of prostate cancer, pending the results of clinical studies, s An easier, faster way to deter mine whether screening does more good than harm would be most welcome, Case control studies may provide some answers. If these studies found that patients with advanced or fatal prostate cancer had been screened less frequently than control subjects, we might conclude that screening is pro tective, In the current practice of what some have called the "PSA era," however, nearly every patient with a new diagnosis of prostate cancer will have had a DRE and PSA test before the diagnosis, Therefore. a key methodologic issue in case-control studies is how to separate screening studies, which should be counted, from diagnostic stud ies, which should not be counted, In this issue Dr, Concato demonstrates why this task is not easy, 4 Traditionally, a test is a screening test when it is done among asymptomatic patients, and it is a diagnostic test when it is done among symptomatic patients. An exception occurs when a symptom is unrelated to the purpose of the test. For example, a PSA test done for a man with a headache is still a screening test for prostate cancer because the headache does not raise the probability of pros tate cancer, This traditional distinction is blurred for cases involving prostatic diseases. The most important issue is whether lower urinary tract symptoms that are consistent with benign prostatic hyperplasia raise the probability of prostate cancer, adjusting for the effect of age, which is related to both these symptoms and pros tate cmlcer. If they do. then almost all DREs and PSA tests are diagnostic tests, because most men over age 50 have at least one lower urinary tract symptom such as occasional nocturia, One proponent of early detection has suggested that this is the case. E' Several studies suggest. however, that these symptoms do not raise the probability of prostate cancer, at least as detected by DREs and PSA tests/-~ If these studies are correct, then all DREs and PSA tests are screening tests, despite the present or ab sence of lower-urinary-tract symptoms, Concato suggests that the truth lies somewhere in between. He has carefully developed a system for classify ing prostate cancer tests into five categories according to how certain the investigator is that they were screening tests. His system is based on the presence and stability of lower-urinary-tract symptoms and on the results of any earlier tests for prostate cancer, Concato used the system to classify DREs in a small number of patients with pros tate cancer. He then conducted a series of case-control studies with hypothetical controls, He found different odds ratios when DREs were classified into different care gories. Although Concato may have overestimated the effect by not allowing for diagnostic testing among controls. his finding that the odds ratio in a case control study is sensitive to the classification of early-detection tests is robust. An important next step is to determine whether different chart abstractors can assign diagnostic tests to the same categories, This classification system will be important in the actual case control study that Concato plans to conduct, and this system or some similar system should be used in other case-control studies investigating this question. A case control study of the ability of screening tests to re duce mortality from prostate cancer will be convincing.
however, only if the odds ratio is relatively insensitive to how tests are classified. The results from Concato's hypo thetical case-control studies suggest that such an outcome should not be counted on too fervently. Nevertheless, case control studies of this problem are important and should be pursued because there is too little information about the effectiveness of current screening prac tices.
If case-control studies do not provide definitive information about whether early detection of prostate cancer reduces mortality, should we expect clinical trials, the usual "gold standard" for effectiveness research, to do better? Perhaps not, at least in the United States. Be cause early detection is so widespread in this country, it will be difficult to prevent the control groups in such trials from becoming "contaminated" by early detection efforts, thus making a negative result unconvincing, at least to REFLECTIONS Go Gently, Little One I helped usher you into our world, little one when the safe haven of your mother's womb stretched and split at the scar of long past births and relieved itself of the burden of your tiny body. We rushed to retrieve you, coddled your heartbeat rejoiced at your first cry, I remember how you reached out to touch your mother's tears in that steel-cold room how you winced when I bundled you and carried you away. Now. after a short vista in human hands I am witness to your exit from this world laden with as much pain and drama as your entry, Once more you arrived pale and empty at our doors but the litany of pumps, needles and tubes could do little this time to restore your soul, We struggle in your absence to understand the edges of life and death and the limits of the enormous privilege we have been given as fellow healers and hummls. And I am reminded, all over again, that it is no small thing to care for those still warm from the hands of God.
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